Cell Therapeutics makes $21 million placement on back of EMA verdict on pixantrone
This article was originally published in Scrip
Cell Therapeutics, Inc. (CTI), the Seattle-based oncology biopharmaceutical firm is set to raise $19.95 million in a private placement that coincides with good news from the European Medicines Agency on its Pixuvri (pixantrone maleate) treatment for paediatric cancer.
You may also be interested in...
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.
What does a good drug launch look like? Is pharma getting better at them? Which drugs are likely still to be in the top 20 in five years' time? Get the picture with Scrip's interactive infographic.